← Back to Search

Other

Asthma Group for Asthma (Nasal-LPS Trial)

Phase 1

Waitlist Available

Research Sponsored by National Jewish Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Participants will have asthma diagnosed by a health care provider

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up we anticipate that the study will run over 5 years

Awards & highlights

Nasal-LPS Trial Summary

This trial is looking at how the body's airways become inflamed in different types of asthma by using a substance found in E. coli bacteria. The study involves giving this substance through the nose to

Who is the study for?

This trial is for adults with asthma diagnosed by a healthcare provider and healthy individuals without asthma. It's not open to those who've used tobacco or marijuana recently, have had nasal surgery, current illness, recent severe asthma issues, nasal polyps, heart/systemic diseases, are pregnant/breastfeeding, have bleeding disorders or compromised immune systems.Check my eligibility

What is being tested?

The study is testing how the body reacts to an intranasal lipopolysaccharide (a component from E. coli) challenge in people with different types of asthma compared to healthy controls. This phase I trial aims to understand airway inflammation mechanisms in various asthma endotypes.See study design

What are the potential side effects?

Potential side effects may include local nasal inflammation or irritation due to the lipopolysaccharide administration. Since this is a phase I study focusing on reactions within the nose following exposure, systemic side effects are less expected.

Nasal-LPS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with asthma by a doctor.

Nasal-LPS Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ we anticipate that the study will run over 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~we anticipate that the study will run over 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and we anticipate that the study will run over 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Neutrophil heterogeneity using single cell RNA sequencing

Nasal-LPS Trial Design

2Treatment groups

Active Control

Group I: Asthma GroupActive Control1 Intervention

Subjects diagnosed with one of the three asthma endotypes being studied (T2, T1, or T17).

Group II: Control GroupActive Control1 Intervention

Subjects with no diagnosis of asthma or other respiratory disease and are deemed healthy.

0 / 1Eligibility criteria met

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

National Jewish HealthLead Sponsor

140 Previous Clinical Trials

316,176 Total Patients Enrolled

23 Trials studying Asthma

17,724 Patients Enrolled for Asthma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available positions for patients to participate in this clinical trial?

"Information on clinicaltrials.gov indicates that recruitment for this study has ceased. Originally posted on April 1, 2024, and last updated on February 13, 2024. However, there are currently 644 other trials actively seeking participants."

Answered by AI

What is the safety profile of Asthma Group for individuals?

"Given the preliminary nature of this Phase 1 clinical trial for the Asthma Group, our team at Power has assigned a safety rating of 1 due to the restricted availability of data supporting both efficacy and safety."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Nasal Inflammation Following Endotoxin Challenge in Patients With Asthma

William Janssen, MD 2024. "Nasal Inflammation Following Endotoxin Challenge in Patients With Asthma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06270576.